Recombinetics Closes $34 Million in Series A Funding

Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, today announced the completion of a $34 million Series A financing round. “We’re [...]

Recombinetics Closes $34 Million in Series A Funding2018-08-21T11:05:04-05:00

Jim Kilman Elected to Recombinetics Board of Directors; Dr. Robert Montgomery Selected as Lead Strategist for Regenerative Medicine Advisory Board

New York-based Expertise Added for Capital Raise and Financing Strategies and Regenerative Medicine Organ Development and Transplantation Program  ST. PAUL, Minn. Recombinetics (RCI), a pioneer [...]

Jim Kilman Elected to Recombinetics Board of Directors; Dr. Robert Montgomery Selected as Lead Strategist for Regenerative Medicine Advisory Board2018-01-17T21:41:43-06:00

RCI Names Dr. Mitchell Abrahamsen as EVP & CCO

Recombinetics (RCI) announced that Dr. Mitchell Abrahamsen has joined RCI as Executive Vice President and Chief Commercial Officer. Dr. Abrahamsen will lead product and business development [...]

RCI Names Dr. Mitchell Abrahamsen as EVP & CCO2017-07-07T14:07:48-05:00
Go to Top